In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection ...

Researchers engineered a CRISPR base editor to correct the ACTA2 mutation causing multisystemic smooth muscle dysfunction ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

Researchers have unveiled a new type of nanostructure that dramatically improves CRISPR delivery. Called lipid nanoparticle ...

Can genetic editing help improve the overall health of people living with type 1 diabetes? The results of a recent study ...

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...

The global CRISPR-based gene editing market size is projected to grow from USD 4.46 billion in 2025 to over USD 13.39 billion by 2034, expanding at a CAGR of 13%. Growth is fueled by advancements in ...

It has long been understood that orchard automation is the key for industry’s profitability and sustainability. As part of ...

VedaBio announces non-exclusive license agreement with Mammoth Biosciences for use of select CRISPR-based technologies in diagnostic applications ...

CRISPR Therapeutics CRSP and Beam Therapeutics BEAM are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...